Literature DB >> 24238848

Accuracy of dedicated risk scores in patients undergoing primary percutaneous coronary intervention in daily clinical practice.

Anibal P Abelin1, Renato B David1, Carlos A Gottschall1, Alexandre S Quadros2.   

Abstract

BACKGROUND: Comparisons between dedicated risk scores in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) in real-world clinical practice are scarce. The aim of this study was to assess the diagnostic performance of the Global Registry of Acute Coronary Events (GRACE), Primary Angioplasty in Myocardial Infarction (PAMI), Thrombolysis in Myocardial Infarction (TIMI), and Zwolle scores in STEMI patients undergoing pPCI in contemporary clinical practice.
METHODS: This was a prospective cohort study of consecutive patients with STEMI undergoing pPCI between December 2009 and November 2010 in a high-volume tertiary referral centre. The outcomes assessed were major cardiovascular events (MACEs) and death within 30 days. The diagnostic accuracy of the scores was assessed using receiver operating characteristic curves, and scores were compared using the DeLong method.
RESULTS: During the study period, 501 patients were included. Within 30 days, 62 patients (12.4%) presented a MACE and 39 individuals (7.8%) died. All scores were statistically associated with death and MACE within 30 days (P < 0.01). The c-statistic and 95% confidence intervals for 30-day mortality were: GRACE, 0.84 (0.78-0.90); TIMI, 0.81 (0.74-0.87); Zwolle, 0.80 (0.73-0.87); and PAMI, 0.75 (0.68-0.82) (P < 0.01). There was no statistically significant difference regarding the accuracy of the TIMI, GRACE, and Zwolle scores for 30-day mortality, but the GRACE score was superior to the PAMI score (P < 0.01).
CONCLUSIONS: The TIMI, GRACE, and Zwolle scores performed equally well as predictors of mortality in patients who underwent pPCI in current practice. These results suggest that these scores are suitable options for risk assessment in a real-world setting.
Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24238848     DOI: 10.1016/j.cjca.2013.07.673

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

1.  The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI.

Authors:  Cihangir Kaymaz; Nurşen Keleş; Nihal Özdemir; İbrahim Halil Tanboğa; Hacer C Demircan; Mehmet M Can; Fatih Koca; İbrahim Akın İzgi; Alper Özkan; Muhsin Türkmen; Cevat Kırma; Ali M Esen
Journal:  Anatol J Cardiol       Date:  2014-12-25       Impact factor: 1.596

2.  Potential economic consequences of a cardioprotective agent for patients with myocardial infarction: modelling study.

Authors:  Talitha I Verhoef; Stephen Morris; Anthony Mathur; Mervyn Singer
Journal:  BMJ Open       Date:  2015-11-13       Impact factor: 2.692

3.  Creation and Implementation of a Prospective and Multicentric Database of Patients with Acute Myocardial Infarction: RIAM.

Authors:  Jacqueline Vaz; Anibal Pereira Abelin; Marcia Moura Schmidt; Pedro Piccaro de Oliveira; Carlos A M Gottschall; Clarissa Garcia Rodrigues; Alexandre Schaan de Quadros
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.